Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 4/20 | 0.64 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.64 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.64 |
| ▸ | AGXT | P21549 | 1/20 | 0.58 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.58 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.47 |
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.42 |
| ▸ | IDH1 | O75874 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL291668 | 0.83 | CYP2A6 (0.70) | CYP2A6ASIC3LOXL2AGXTADRB2 | |
| SCHEMBL4961407 | 0.82 | CYP2A6 (0.69) | CYP2A6ASIC3LOXL2AGXTADRB2 | |
| SCHEMBL3030176 | 0.79 | CYP2A6 (0.55) | CYP2A6ASIC3LOXL2AGXTADRB2 | |
| SCHEMBL9810053 | 0.78 | CYP2A6 (0.64) | CYP2A6ASIC3LOXL2AGXTADRB2 | |
| SCHEMBL18666283 | 0.78 | CYP2A6 (0.64) | CYP2A6ASIC3LOXL2AGXTADRB2 | |
| SCHEMBL1522855 | 0.78 | CYP2A6 (0.64) | CYP2A6ASIC3LOXL2AGXTADRB2 | |
| SCHEMBL2568843 | 0.78 | CYP2A6 (0.64) | CYP2A6ASIC3LOXL2AGXTADRB2 | |
| SCHEMBL240588 | 0.78 | CYP2A6 (1.00) | CYP2A6ASIC3LOXL2AGXTADRB2 | |
| SCHEMBL355949 | 0.78 | CYP2A6 (1.00) | CYP2A6ASIC3LOXL2AGXTADRB2 | |
| SCHEMBL3113989 | 0.78 | CYP2A6 (0.64) | CYP2A6ASIC3LOXL2AGXTADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803822-B2 | Triazole derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-28 | — | — | US | disclosed |
| US-20090105253-A1 | Triazole Derivative and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-23 | — | — | US | disclosed |
| EP-1867331-A1 | TRIAZOLE DERIVATIVE AND THE USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2007-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105253-A1 | Triazole Derivative and Use Thereof | F2R, HRH4, F2RL3 | CYP2A6 1122/4885ASIC3 2279/4885LOXL2 3920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.